5:39 PM
 | 
Sep 05, 2012
 |  BC Extra  |  Company News

NPS delays BLA submission for hypoparathyroidism therapy

NPS Pharmaceuticals Inc. (NASDAQ:NPSP) delayed its planned submission of a BLA to FDA for hypoparathyroidism product Natpara to...

Read the full 80 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >